

ONLINE DATA SUPPLEMENT FOR:

β -adrenergic Receptor Polymorphisms and Response to Salmeterol

**Michael E. Wechsler¹, MD, MMSc, Erik Lehman², MS, Stephen C. Lazarus³, MD,
Robert F. Lemanske, Jr.⁴, MD, Homer A. Boushey³, MD, Aaron Deykin¹, MD, John
V. Fahy³, MD, ChB, Christine A. Sorkness⁴, PharmD, Vernon M. Chinchilli², PhD,
Timothy J. Craig², DO, Emily DiMango⁵, MD, Monica Kraft⁶, MD, Frank Leone⁷,
MD, Richard J. Martin⁸, MD, Stephen P. Peters⁹, MD, PhD, Stanley J. Szefler⁸,
MD, Wenlei Liu², PhD and Elliot Israel¹, MD for The National Heart, Lung, And
Blood Institute's Asthma Clinical Research Network**

Online Repository Figure 1. AM Peak flow in subjects receiving albuterol regularly or as needed, stratified by B16 genotype, in the BAGS study⁶. The decline in AM PEF with albuterol in ARG/ARG subjects in the BAGS trial is remarkably similar to the response to salmeterol in the currently reported trial (From reference 6, Israel et al AJRCCM 2000)

Online repository table 1:

SOCS and SLIC Beta2-Adrenergic receptor polymorphism genotyping success rates

B2 receptor Marker	Genotyping Success Rate
C-709A	0.928
G-654A	0.899
C-47T	0.941
A+46G	0.872
C+79G	0.899
G+252A	0.848
C+491T	0.896
C+523A	0.920

Online repository Table 2: AM PEF Change from baseline in both homozygote and heterozygote B16 subjects in SOCS and SLIC

Outcomes	SOCS and SLIC Heterozygotes, change from baseline									
	A/A		G/G		A/G		A/A- A/G		G/G - A/G	
	Difference	P-value	Difference	P-value	Difference	P-value	Difference	P-value	Difference	P-value
SOCS AM Peak Flow, L/min, week 22, compared with placebo	-29.90 (-58.47, -1.33)	0.04	21.50 (-0.01, 43.0)	0.05	18.18 (2.30, 34.06)	0.03	-48.08 (-80.77,-15.39)	0.004	3.32 (-30.05, 23.42)	0.81
SLIC AM Peak Flow L/min, week 24	-18.41 (-55.8,18.9)	0.33	17.79 (-3.6,39.2)	0.10	44.3 (25.0,63.6)	<0.0001	-62.71 (-104.8,-20.6)	0.004	-26.51 (-55.4,2.3)	0.07

Online repository Figure 1

